TMS Enrolls First Japanese Patient in Global Phase II/III Stroke Trial of TMS-007

An announcement from TMS Co., Ltd. ( (JP:4891) ) is now available.

TMS Co., Ltd. said it has enrolled the first patient in the Japan cohort of the global Phase II/III ORION trial of TMS-007 (JX10), an intravenous therapy for acute ischemic stroke designed to be given between 4.5 and 24 hours after patients were last known well. The multicenter, double-blind study, sponsored globally by Corxel Pharmaceuticals, will recruit about 740 participants across more than 150 sites in over 20 countries to evaluate functional outcomes at 90 days.

TMS-007 (JX10) combines thrombolytic and anti-inflammatory mechanisms and aims to extend the treatment window beyond the current 4.5-hour standard, potentially expanding access to effective stroke care for many patients. Earlier Phase II data from Japan showed significantly improved 90-day clinical outcomes and supportive angiographic results versus placebo, positioning the ongoing ORION trial as a critical step in confirming efficacy and safety and potentially strengthening TMS’s role in the global stroke treatment market.

The most recent analyst rating on (JP:4891) stock is a Hold with a Yen132.00 price target. To see the full list of analyst forecasts on TMS Co., Ltd. stock, see the JP:4891 Stock Forecast page.

More about TMS Co., Ltd.

TMS Co., Ltd. is a clinical-stage biopharmaceutical company developing transformative medicines for serious diseases with high unmet medical need. Its pipeline centers on SMTP small-molecule compounds derived from a fungus, led by TMS-007 (JX10) for acute ischemic stroke, and includes programs in resistant hypertension, acute kidney injury, and spinal cord injury, often advanced via collaborations with Japanese academic institutions.

Average Trading Volume: 287,508

Technical Sentiment Signal: Strong Sell

Current Market Cap: Yen6.05B

Learn more about 4891 stock on TipRanks’ Stock Analysis page.